Rezolute Reports Positive Interim Phase 3 Data for Ersodetug in Treating Congenital Hyperinsulinism

Rezolute released interim data from its Phase 3 upLIFT clinical trial on Tuesday, reporting that the drug candidate ersodetug met its primary endpoints in treating patients with congenital hyperinsulinism. The study evaluated the efficacy and safety of the treatment in managing blood glucose levels for individuals diagnosed with the rare metabolic disorder.

The trial data indicates that patients receiving ersodetug maintained stable glucose levels throughout the study period, showing a reduction in the frequency of hypoglycemic events compared to baseline measurements. Researchers monitored participants for adverse reactions to assess the drug’s safety profile, noting that the interim results align with the study’s pre-defined clinical objectives. Rezolute plans to continue the upLIFT study to gather further long-term data, which the company intends to submit to regulatory authorities for future review.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI